Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?

Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.

Zacks Investment Research • Jun 11, 2026

Nasdaq Quant Leaders: 5 Top Stocks Averaging 272% Forward EPS Growth

AI-fueled earnings growth helped drive Nasdaq to record highs in 2026, despite valuation concerns, macro headwinds, and geopolitical tensions. Nasdaq-100 earnings grew 46% YoY in Q1, led by AI hyperscalers, but contributions broadened beyond big tech. Earnings remain the ultimate driver of long-term equity performance, according to Nasdaq economists, with the index significantly outperforming the S&P 500 over the past two decades.

Seeking Alpha • Jun 10, 2026

IRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation Use

Ironwood gains FDA approval to expand Linzess use to children aged two to five years with functional constipation.

Zacks Investment Research • May 28, 2026

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4th at 11:05 a.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceutic.

Business Wire • May 28, 2026

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of LINZESS® (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). LINZESS was previously approved for pediatric patients 6 years and older with FC. With thi.

Business Wire • May 27, 2026

Ironwood Pharmaceuticals: A Contrarian Buy Opportunity

Ironwood Pharmaceuticals presents a contrarian buy opportunity after a 14.5% decline driven by CFO resignation and insider selling. At the current $3.49 quote, IRWD fundamentals remain intact, supported by an SA Quant STRONG BUY rating and a base-case target of $6.90, implying ~100% upside. Short-term volatility is attributed to management changes and insider sales, but underlying cash generation and business model remain intact.

Seeking Alpha • May 22, 2026

Ironwood Pharmaceuticals: CFO Resignation Knocks Shares - A Downgrade Is Due

Ironwood Pharmaceuticals is downgraded to Hold after the CFO's resignation and despite record Q1 2026 Linzess-driven revenues. IRWD guides for $1.125–$1.175bn in Linzess sales and $450–$475m in total revenues in 2026 but faces 2027 Medicare price cuts and 2029 generic entry. Apraglutide's Phase 3 confirmatory trial launches in 2026, but competitive and regulatory hurdles cloud its $700m peak sales potential.

Seeking Alpha • May 13, 2026

Ironwood Pharmaceuticals Q1 Earnings Call Highlights

Ironwood Pharmaceuticals NASDAQ: IRWD reported a strong start to 2026 and reiterated its full-year outlook, pointing to sharp first-quarter growth for LINZESS and continued progress toward a confirmatory phase III program for apraglutide in short bowel syndrome with intestinal failure (SBS-IF).

MarketBeat • May 8, 2026

Ironwood Stock Down Despite Q1 Earnings and Revenue Beat

IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.

Zacks Investment Research • May 8, 2026

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026